JP2018514576A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018514576A5 JP2018514576A5 JP2017557405A JP2017557405A JP2018514576A5 JP 2018514576 A5 JP2018514576 A5 JP 2018514576A5 JP 2017557405 A JP2017557405 A JP 2017557405A JP 2017557405 A JP2017557405 A JP 2017557405A JP 2018514576 A5 JP2018514576 A5 JP 2018514576A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- combination according
- cd16a
- combination
- multifunctional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15166303.6 | 2015-05-04 | ||
| EP15166303.6A EP3091031A1 (en) | 2015-05-04 | 2015-05-04 | Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor |
| EP16152650.4 | 2016-01-25 | ||
| EP16152650 | 2016-01-25 | ||
| PCT/EP2016/060113 WO2016177846A1 (en) | 2015-05-04 | 2016-05-04 | Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018514576A JP2018514576A (ja) | 2018-06-07 |
| JP2018514576A5 true JP2018514576A5 (enExample) | 2019-06-13 |
| JP6609784B2 JP6609784B2 (ja) | 2019-11-27 |
Family
ID=56026814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557405A Active JP6609784B2 (ja) | 2015-05-04 | 2016-05-04 | 治療のためのｃｄ３０×ｃｄ１６抗体とｐｄ−１アンタゴニストとの組み合わせ |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11167029B2 (enExample) |
| EP (1) | EP3292153B1 (enExample) |
| JP (1) | JP6609784B2 (enExample) |
| CN (1) | CN107847587B (enExample) |
| AU (1) | AU2016257334B2 (enExample) |
| BR (1) | BR112017023579A2 (enExample) |
| CA (2) | CA3219372A1 (enExample) |
| CY (1) | CY1122283T1 (enExample) |
| DK (1) | DK3292153T3 (enExample) |
| ES (1) | ES2754557T3 (enExample) |
| HR (1) | HRP20191933T1 (enExample) |
| HU (1) | HUE045866T2 (enExample) |
| LT (1) | LT3292153T (enExample) |
| PL (1) | PL3292153T3 (enExample) |
| PT (1) | PT3292153T (enExample) |
| RS (1) | RS59489B1 (enExample) |
| RU (1) | RU2761352C2 (enExample) |
| SI (1) | SI3292153T1 (enExample) |
| SM (1) | SMT201900598T1 (enExample) |
| WO (1) | WO2016177846A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3052886A1 (en) | 2017-02-28 | 2018-09-07 | Affimed Gmbh | Combination of an anti-cd16a antibody with a cytokine |
| CA3051062C (en) | 2017-02-28 | 2023-09-26 | Affimed Gmbh | Tandem diabody for cd16a-directed nk-cell engagement |
| CN109706164A (zh) * | 2017-10-26 | 2019-05-03 | 深圳新诺微环生物科技有限公司 | 微环dna表达连接人和猴cd20与效应细胞抗原的桥接分子及其应用 |
| CN109706163A (zh) * | 2017-10-26 | 2019-05-03 | 深圳新诺微环生物科技有限公司 | 微环dna表达连接人与动物靶细胞与效应细胞的桥接分子及其应用 |
| KR102924742B1 (ko) * | 2018-03-14 | 2026-02-10 | 아피메트 게엠베하 | 이중특이적 egfr/cd16 항원-결합 단백질 |
| EP3774914A2 (en) * | 2018-04-13 | 2021-02-17 | Affimed GmbH | Nk cell engaging antibody fusion constructs |
| RS65658B1 (sr) * | 2018-08-27 | 2024-07-31 | Affimed Gmbh | Kriokonzervirane nk ćelije prethodno punjene konstruktom antitela |
| CN109402168A (zh) * | 2018-10-30 | 2019-03-01 | 深圳新诺微环生物科技有限公司 | 微环dna表达连接her2阳性细胞与效应细胞的桥接分子及其应用 |
| KR20220048988A (ko) * | 2019-06-11 | 2022-04-20 | 마이얼로이드 테라퓨틱스, 인크. | 대식세포 특이적 인게이저 조성물 및 이의 사용 방법 |
| AU2020414409A1 (en) * | 2019-12-27 | 2022-06-16 | Affimed Gmbh | Method for the production of bispecific FcyRIIl x CD30 antibody construct |
| CA3209579A1 (en) * | 2021-01-27 | 2022-08-04 | Innovent Biologics (Suzhou) Co., Ltd. | Single-domain antibody against cd16a and use thereof |
| US20240343811A1 (en) | 2021-06-29 | 2024-10-17 | Shandong Simcere Biopharmacutical Co., Ltd. | Cd16 antibody and use thereof |
| AR127298A1 (es) | 2021-10-08 | 2024-01-10 | Genmab As | Anticuerpos que se unen a cd30 y cd3 |
| JP2024542159A (ja) * | 2021-11-04 | 2024-11-13 | アーティバ バイオセラピューティクス インコーポレイテッド | Ｎｋ細胞と多重特異性エンゲージャーとによるがんの処置 |
| WO2023080895A1 (en) * | 2021-11-04 | 2023-05-11 | Artiva Biotherapeutics, Inc. | Treatment of cancer with nk cells and multispecific engagers |
| CN116059348A (zh) * | 2022-09-16 | 2023-05-05 | 四川大学华西医院 | 基于nkg2d的细胞接合器分子在清除衰老细胞中的应用 |
| CN120077072A (zh) | 2022-11-29 | 2025-05-30 | 江苏恒瑞医药股份有限公司 | Cldn18.2/4-1bb结合蛋白及其医药用途 |
| CN121240884A (zh) | 2023-04-05 | 2025-12-30 | 根马布股份公司 | 包含与cd30和cd3结合的抗体的药用组合物 |
| CN117442721B (zh) * | 2023-12-20 | 2024-03-15 | 苏州艾凯利元生物科技有限公司 | 一种包括nk细胞和nk细胞接合器分子的组合物 |
| CN118791616A (zh) * | 2024-09-14 | 2024-10-18 | 苏州为度生物技术有限公司天津分公司 | 一种抗人cd16工程抗体及应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| KR101510065B1 (ko) * | 2005-06-08 | 2015-04-07 | 다나-파버 캔서 인스티튜트 인크. | 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물 |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| US20170247455A1 (en) * | 2014-08-22 | 2017-08-31 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
-
2016
- 2016-05-04 PT PT167239680T patent/PT3292153T/pt unknown
- 2016-05-04 HU HUE16723968A patent/HUE045866T2/hu unknown
- 2016-05-04 ES ES16723968T patent/ES2754557T3/es active Active
- 2016-05-04 CN CN201680026411.5A patent/CN107847587B/zh active Active
- 2016-05-04 SM SM20190598T patent/SMT201900598T1/it unknown
- 2016-05-04 SI SI201630463T patent/SI3292153T1/sl unknown
- 2016-05-04 AU AU2016257334A patent/AU2016257334B2/en active Active
- 2016-05-04 BR BR112017023579A patent/BR112017023579A2/pt active Search and Examination
- 2016-05-04 PL PL16723968T patent/PL3292153T3/pl unknown
- 2016-05-04 RS RS20191372A patent/RS59489B1/sr unknown
- 2016-05-04 EP EP16723968.0A patent/EP3292153B1/en active Active
- 2016-05-04 WO PCT/EP2016/060113 patent/WO2016177846A1/en not_active Ceased
- 2016-05-04 LT LT16723968T patent/LT3292153T/lt unknown
- 2016-05-04 DK DK16723968.0T patent/DK3292153T3/da active
- 2016-05-04 CA CA3219372A patent/CA3219372A1/en active Pending
- 2016-05-04 CA CA2983706A patent/CA2983706C/en active Active
- 2016-05-04 HR HRP20191933TT patent/HRP20191933T1/hr unknown
- 2016-05-04 JP JP2017557405A patent/JP6609784B2/ja active Active
- 2016-05-04 RU RU2017137251A patent/RU2761352C2/ru active
-
2017
- 2017-10-19 US US15/788,177 patent/US11167029B2/en active Active
-
2019
- 2019-10-25 CY CY20191101115T patent/CY1122283T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191933T1 (hr) | Kombinacija anti-cd30xcd16a antitijela s antagonističkim anti-pd-1 antitijelom za terapiju | |
| WO2016011210A3 (en) | Engineered cells for adoptive cell therapy | |
| EP4249066A3 (en) | Antibodies to tigit | |
| ZA202006943B (en) | Chimeric receptors to dll3 and methods of use thereof | |
| WO2011159877A3 (en) | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions | |
| JP2016531907A5 (enExample) | ||
| JP2015535691A5 (enExample) | ||
| HK1249423A1 (zh) | 能够结合b7-h3和cd3的双特异性单价双抗体及其用途 | |
| FI3303396T3 (fi) | Vasta-aineita ox40:ää vastaan ja niiden käyttöjä | |
| PH12018501778A1 (en) | Antibodies to tigit | |
| AU2018282094A1 (en) | Antibodies that specifically bind PD-1 and methods of use | |
| MX2021002190A (es) | Estrategia de dosificacion que mitiga el sindrome de liberacion de citoquinas para los anticuerpos biespecificos cd3/cd20. | |
| NZ743124A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
| JO3740B1 (ar) | روابط pd1/ctla4 | |
| WO2014028560A3 (en) | T-cell redirecting bispecific antibodies for treatment of disease | |
| WO2016154003A8 (en) | Neutralizing antibodies to gp120 and their use | |
| JP2018508483A5 (enExample) | ||
| EA201790953A1 (ru) | Изменение экспрессии гена в cart-клетках и их применения | |
| JP2017508744A5 (enExample) | ||
| JP2018500337A5 (enExample) | ||
| HK1210792A1 (en) | Molecules with antigen binding and polyvalent fc gamma receptor binding activity | |
| WO2015127405A3 (en) | Anti-il-13/il-17 bispecific antibodies and uses thereof | |
| WO2020136145A3 (en) | Leucocyte immunoglobulin-like receptor 2 neutralizing antibodies | |
| MY171226A (en) | Antibodies that bind il-23 | |
| WO2016161415A3 (en) | Tnfrsf14/ hvem proteins and methods of use thereof |